A structure, method, and computer program product for a diabetes control system provides, but is not limited thereto, the following: open-loop or closed-loop control of diabetes that adapts to individual physiologic characteristics and to the behavioral profile of each person. An exemplary aspect to this adaptation is biosystem (patient or subject) observation and modular control. Consequently, established is the fundamental architecture and the principal components for a modular system, which may include algorithmic observers of patients' behavior and metabolic state, as well as interacting control modules responsible for basal rate, insulin boluses, and hypoglycemia prevention.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
2.
METHODS OF MODELING IN VIVO EFFICACY OF DRUG COMBINATIONS FOR TREATMENT OF VIRAL INFECTIONS
Methods of modeling the in vivo efficacy of drug combinations for the treatment or prevention of viral infection are described. The described methods combine data for single drugs and drug combinations from pharmacokinetic, pharmacodynamic, and viral dynamics models under a series of estimated in vivo drug potencies to provide predictions of the in vivo effects of the drug combinations. These predictions can be used to more accurately select drugs and drug treatment regimens that can be successful in controlling viral infection in animal studies, clinical trials and in medical or veterinary interventions. Also described is a method of treating or preventing filovirus infections using combinations of orally available drugs based on predictions from the modeling methods.
G16H 70/40 - ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
3.
TRANSPORT PROPERTY MODULATION VIA SOLVENT SPECIFIC BEHAVIOR IN CROSSLINKED NON-AQUEOUS MEMBRANES
Nonaqueous redox flow batteries are one economically promising solution for meeting grid-scale energy storage needs at discharge durations of 10 h or more. However, membrane transport properties in nonaqueous systems are not as well understood as in water. Solvent-specific effects complicate efforts to understand transport in nonaqueous. In one aspect, the disclosure relates to blended cross-linked membranes compositions, methods of making same, and devices, products, and systems comprising same. In one aspect, the disclosed blended cross-linked membranes compositions comprise a cross-linked first polymer and a second polymer. The disclosed blends have desired permeabilities for selected cations and rejected undesired materials from the redox reaction mixture. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
In some aspects, the techniques described herein relate to a method of processing a photovoltaic module structure including multiple layers, the method including: irradiating the photovoltaic module structure with a laser emission to target a specified layer with the laser emission using a specified wavelength of the laser emission; wherein the irradiating includes at least one of: delaminating at least a portion of the specified layer of the photovoltaic module structure from an adjacent layer amongst the multiple layers; or repairing a defect in the specified layer photovoltaic module structure; or both.
Provided are compositions that include targeting peptides and methods for using the same to treat and/or prevent various diseases, disorders, and/or conditions. In some embodiments, the compositions and methods relate to liposomal compositions that include a liposome, the surface of which is conjugated to a peptide having an amino acid sequence as set forth in any of SEQ ID NOS: 3-38, optionally wherein the liposome encapsulates a therapeutic agent or a detectable agent. In some embodiments, the peptide has an amino acid sequence that is one of SEQ ID NOs: 14, 19, 20, 27, and 28. Also provided are methods treating or preventing fibrosis, for decreasing the incidence of a disease, disorder, or condition associated with chronic pancreatitis (CP), for targeting active agents to targets, including but not limited to collagen III-expressing cells and extracellular matrix, and for decreasing incidence of side effects associated with apigenin treatment.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
A61P 5/00 - Drugs for disorders of the endocrine system
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
Disclosed are compositions and methods for treating a disease or disorder such as cancer in a subject in need thereof. In some aspects, the method comprises administering to the subject a vector comprising a first nucleic acid sequence encoding a promoter operably linked to each of a second nucleic acid sequence encoding a therapeutic polypeptide, and a third nucleic acid sequence encoding a peptide domain that is stabilized when phosphorylated by kinase activity in a target tissue. The kinase activity can be elevated extracellular regulated kinase (ERK) activity.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Embodiments relate to a dynamic spectrum access (DSA) system including a DSA transmitter configured to generate a complex signal for a secondary communication system, the complex signal being within a communication band A that is equal to or falls within a communication band B of a primary communication system. The complex signal includes a first signal and a second signal that is a repeat of the first signal. The power of the complex signal received at the secondary communication receiver is greater than the noise floor of the secondary communication system, but is equal to or less than the interference power from the primary communication. The DSA system includes a DSA receiver including a plurality of DSA antennas and a DSA signal processing module, the DSA signal processing module configured to perform canonical correlation analysis (CCA) on the complex signal.
METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING PROSTATE CANCER BASED ON LONG NONCODING RNA OVERLAPPING THE LCK GENE THAT REGULATES PROSTATE CANCER CELL GROWTH
Provided herein is a previously unannotated IncRNA lying within exon six and 3′UTR of the LCK gene, labeled “HULLK” for Hormone-Upregulated IncRNA within LCK. HULLK is a novel IncRNA situated within the LCK gene that can serve as an oncogene in PCa. Accordingly, provided are methods and compositions for diagnosing and treating prostate cancer based on HULLK that regulates prostate cancer cell growth.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
9.
COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHIC ATROPHY
It is disclosed herein that RPE degeneration in human cell culture and in mouse models is driven by a non-canonical inflammasome pathway that results in activation of caspase-4 (also known as caspase-11 in mouse) and caspase-1, and requires cyclic GMP-AMP synthase (cGAS)-dependent interferon-β (IFN-β) production and gasdermin D-dependent interleukin-18 (IL-18) secretion. Reduction of DICER1 or accumulation of Alu RNA triggers cytosolic escape of mitochondrial DNA, which engages cGAS. Collectively, these data highlight an unexpected role for cGAS in responding to mobile element transcripts, reveal cGAS-driven interferon signaling as a conduit for mitochondrial damage-induced NLRP3 activation, and expand the immune sensing repertoire of cGAS and caspase-4 to non-infectious human disease. Coupled with the unexpected result that caspase-4, gasdermin D, IFN-β, and cGAS are elevated in the RPE of human eyes with geographic atrophy, these findings also identify new targets for a major cause of blindness.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
10.
SYK ACTIVATORS AND INHIBITORS IN NEURODEGENERATIVE DISEASES
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
A61K 31/501 - Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/505 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
11.
VIBRATION BASED INTERACTION SYSTEM FOR ON BODY DEVICE AND METHOD
Disclosed are various embodiments for recognition of on body touch interactions and gestures using an on-body device. A sample of vibration data from the vibration sensor is input into a trained convolutional neural network. The vibration data is generated from a vibration event. In response, the trained convolutional neural network outputs one of a plurality of predefined vibration event descriptors. The trained convolutional neural network is adapted based at least in part on a plurality of Siamese contrastive loss calculations. Each Siamese contrastive loss calculation is generated from a corresponding pair of preexisting samples of vibration data from a pool of preexisting samples of vibration data.
Disclosed herein are low dielectric constant (low-k) two-dimensional covalent organic framework materials that have a dielectric constant k less than 2.4, optionally less than 1.9, and are comprised of regularly porous, covalently linked, layer structures.
Provided are compositions and methods for treating and/or preventing seizure-induced death in subjects in need thereof. In some embodiments, the methods include methods for inducing an audiogenic seizure and/or seizure-induced death, treating and/or preventing death associated with seizures in subjects, preventing sudden unexpected death in epilepsy (SUDEP) in subjects, preventing and/or reducing the risk of death in subjects having SCN8A gain-of-function mutations, preventing or reducing the risk of death associated with tonic seizures in subjects, and preventing or reducing the risk of death associated with epileptic seizures in subjects. Also provided are animals that have been modified to carry gain-of-function SCN8A mutations and methods for using the same to identify compounds that have activity in treating and/or preventing seizures and/or seizure-induced death in subjects.
Disclosed are methods, including automated methods, for identifying a compound that impacts a characteristic of a lipid raft phase domain, a characteristic of a non-raft phase domain, and/or a characteristic of one or more membrane proteins. In some embodiments, the method comprises contacting a population of vesicles with a candidate compound, wherein a population of vesicles, wherein one or more vesicles in the population of optionally comprises one or more membrane proteins, with a candidate compound, wherein in a portion of the population of vesicles there is only a single detectable membrane phase and in a portion of the population of vesicles a membrane lipid raft phase domain and a membrane non-raft phase domain are phase separated; detecting a signal from the population of vesicles; and identifying the candidate compound as having an impact on a characteristic of a lipid raft phase domain, a characteristic of a non-raft phase domain, and/or a characteristic of one or more membrane proteins based on the signal. Systems and non-transitory computer readable medium comprising computer executable instructions embodied in a computer readable medium that when executed by a processor of a computer control the computer to perform steps of the method are also disclosed.
Provided are methods for treating subjects with coronavirus infections. The methods include providing a subject infected with a coronavirus resulting in a prothrombotic condition in addition to being infected by a coronavirus, and administering to the subject an angiotensin (1-7) peptide or an analog or derivative thereof, a Mas Receptor (MasR) agonist, or any combination thereof. The subject may be suffering from COVID-19 disease, including but not limited to a thrombotic complication, an adverse pregnancy outcome, and/or a complication resulting from an underlying prothrombotic state. Also provided are compositions that include Ang (1-7) peptides, analogs, and/or derivatives thereof that are associated with degradable and/or non-degradable polymers having electrostatic interactions therewith, hydrophobic interaction therewith, hydrogen bonding interactions therewith, or any combination thereof. Also provided are uses of Ang (1-7) peptides, analogs, and/or derivatives thereof and/or a Mas Receptor (MasR) agonists for treating subjects infected with coronaviruses and/or for preparing medicaments therefore.
Methods for treating coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, are described. The methods can be used to reduce the severity of outcomes related to COVID-19, such as hospitalization and ventilation. For example, the methods can involve treatment of a subject with a therapeutic agent that degrades hyaluronan and/or an agent that neutralizes a hyaluronan receptor, e.g., CD44, such as an anti-CD44 antibody.
A computerized system calculates a composite index for sets of functional movement scores that quantify motor function abilities for patients. Wearable sensors, kinetic energy sensors, ultrasound imagers, and force sensors are used to store the composite index from predictors of the functional movement scores, the predictors comprising a respective shape of motion factor, a respective motion symmetry factor, and a respective motion speed factor for each of the sets of functional movement scores. The software tabulates the respective composite index by calculating a probability that the respective shape of motion factor, the respective motion symmetry factor, and the respective motion speed factor correspond to one of the sets of functional movement scores.
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
Methods and systems for producing graphene from spent lithium-ion batteries are disclosed. One method includes applying an acid leaching solution to an anode of a lithium-ion battery to produce expanded graphite, applying a hydrothermal process to the expanded graphite to produce purified graphite, and subjecting the purified graphite to a shear mixing process to produce dispersed graphene. In some examples, the shear mixing process is combined with a hydrogen passivation process, which collectively improves each of graphene quality, graphene conversion rate, and graphene production efficiency.
Provided are peptides, modified peptides, fragments thereof, conjugates thereof, and polymers thereof that have antibacterial activity, including against multidrug-resistant bacteria. In some embodiments, the peptides include amino acid sequences as set forth in any of SEQ ID NOs: 2-151, modified peptides, fragments, and conjugates thereof, and any combination thereof. The peptides, modified peptides, fragments, and conjugates can be polymer- functionalized, encapsulated in a particle, embedded in and/or on a solid support, impregnated in a dressing, and/or is formulated for use in a nebulizer, for topical administration, and/or for systemic administration. Also provided are medical devices having an antibacterial agent embedded in and/or associated with a support layer, and methods for inhibiting growth of and/or killing bacteria, for treating or preventing community and/or nosocomial infections, for treating bacterial infections present in wounds, for treating pulmonary infections, for treating or preventing systemic bacterial infections, and for combination therapies with conventional antibiotics.
METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING PROSTATE CANCER BASED ON LONG NONCODING RNA OVERLAPPING THE LCK GENE THAT REGULATES PROSTATE CANCER CELL GROWTH
Provided herein is a previously unannotated IncRNA lying within exon six and 3′UTR of the LCK gene, labeled “HULLK” for Hormone-Upregulated IncRNA within LCK. HULLK is a novel IncRNA situated within the LCKgene that can serve as an oncogene in PCa. Accordingly, provided are methods and compositions for diagnosing and treating prostate cancer based on HULLK that regulates prostate cancer cell growth.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
22.
SYSTEMS AND METHODS FOR CONTEXT-AWARE ANXIETY INTERVENTIONS
The University of Virginia Patent Foundation (USA)
Inventor
Teachman, Bethany A.
Barnes, Laura E.
Boukhechba, Mehdi
Abstract
An anxiety microdose intervention delivery system receives, from a plurality of biomarker sensors, a positional parameter associated with a user's position, a social parameter associated with a user's social interaction, and a set of physiological parameters associated with a user's physiological state. The system can determine, using a recommendation algorithm, that a user is in a possible state of anxiety. The system can generate, based at least in part on the determination that the user is in the possible state of anxiety, data for displaying microdose intervention content on the user device. The microdose intervention content can be configured to better manage the anxiety. The system can receive user interaction with the microdose intervention content and transmit a report of the user interaction with the intervention content.
UNIVERSITY OF OTTAWA INSTITUTE OF MENTAL HEALTH RESEARCH (IMHR) (Canada)
Inventor
Payne, Jennifer
Kaminsky, Zachary
Abstract
The present invention relates to the field of Premenstrual dysphoric disorder (PMDD) and perimenopausal depression (PMD). More specifically, the present invention relates to the use of biomarkers to diagnose PMDD, PMD or predict a risk thereof. In one embodiment, a method for identifying a likelihood of PMDD and/or PMD in a patient comprises the steps of (a) providing a sample from the patient; (b) measuring white blood cell type counts and DNA methylation levels of a panel of biomarkers or using a proxy marker to estimate the ratio monocytesmon-monocytes in the sample collected from the patient, wherein the panel of biomarkers comprises HP1BP3 and TTC9B and the white blood cell type counts comprise monocytes and non-monocytes; and (c) using a linear model that utilizes the DNA methylation level of HP1BP3 and TTC9B and the ratio of monocytesmon-monocytes or proxy marker to determine the patient is likely to develop PMDD and/or PMD.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
24.
MICROFLUIDIC SYSTEM AND METHOD FOR DNA METHYLATION SAMPLE PREPARATION
Various aspects disclosed relate to a centrifugal microfluidic device to perform dynamic solid phase sodium bisulfate conversion. The device includes a reaction assembly. The reaction assembly includes a plurality of individual chambers, each including a bisulfate conversion chamber, an elution chamber, a magnetic manipulation chamber, a waste chamber, and a buffer chamber. The reaction assembly further includes at least one valve configured to selectively establish or prevent fluid communication along a channel between at least two respective individual chambers amongst the plurality of individual chambers. Additionally, the reaction assembly is configured to establish fluidic transport in response to rotation about an axis intersecting a central region of the reaction assembly and perpendicular to a plane on which the reaction assembly is disposed.
A method for performing dynamic positron emission tomography (PET) is disclosed. The method includes collecting volumetric radioactive measurement data associated with an administered radioactive tracer present in a target site of a subject over multiple scanning intervals, capturing a magnetic resonance image of the target site, and performing a motion correction process to the volumetric radioactive measurement data to produce motion corrected PET data. The method further includes co-registering the magnetic resonance image and motion corrected data to generate a co-registered dynamic PET volume, and applying a model corrected input function (MCIF) to the co-registered dynamic PET volume to calibrate an uptake amount of the radioactive tracer in the target site.
A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G06T 7/30 - Determination of transform parameters for the alignment of images, i.e. image registration
26.
SYSTEM AND METHOD FOR BODY MASS INDEX RELATION TO PATIENT DIFFERING PSYCHOLOGICAL STRESS EFFECT ON BLOOD GLUCOSE DYNAMICS IN PATIENTS WITH INSULIN DEPENDENT DIABETES
An insulin device configured to control insulin dispensing based on insulin sensitivity. The insulin device includes a processor configured to receive insulin dosing schedule information, psychological stress level data, and body mass index (BMI) data; a sensor configured to generate a blood glucose level measurement. The sensor is calibrated as a function of the psychological stress level data and the BMI data and the processor is configured to monitor and detect changes of the blood glucose level measurement that are determined to have occurred as a function of changes of the psychological stress level data, and identify a time when the BMI data counteracts a detected change in the blood glucose level measurement. The insulin device also includes an insulin dispensing valve controlled by the processor to change the insulin dosing schedule information in accordance with the counteracting BMI data.
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
Some embodiments relate to therapeutic radioisotopic particles. In some embodiments, the therapeutic particles are radiolabeled with therapeutic radioisotopes. In some embodiments, the therapeutic particles can be in the treatment of cancer of the liver. In some embodiments, the therapeutic particles are radiolabeled with therapeutic radioisotopes. In some embodiments, the therapeutic radioisotope is directly coupled to a surface of a substrate of the particle.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
A61K 51/02 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier
An exemplary method and system are disclosed that employ DENSE deep learning neural-network(s) trained with displacement-encoded imaging data (i.e., DENSE data) to estimate intramyocardial motion from cine MRI images and other cardiac medical imaging modalities, including standard cardiac computer tomography (CT) images, magnetic resonance imaging (MRI) images, echocardiogram images, heart ultrasound images, among other medical imaging modalities described herein. The DENSE deep learning neural-network(s) can be configured (trained) using (i) contour motion data from displacement-encoded imaging magnitude data as inputs to the neural network and (ii) displacement maps derived from displacement-encoded imaging phase images for comparison to the outputs of the neural network for neural network adjustments during the training.
G06T 3/40 - Scaling of a whole image or part thereof
G06T 7/246 - Analysis of motion using feature-based methods, e.g. the tracking of corners or segments
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
29.
ENHANCED DETECTION OF BIOFILM-EMBEDDED AND ADHERED PATHOGENS ON CONTAMINATED FOODS OR SURFACES USING ENZYMES
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (USA)
UNIVERSITY OF VIRGINIA PATENT FOUNDATION (USA)
Inventor
Capobianco, Joseph, A.
Lee, Joseph
Chen, Chin Yi
He, Yiping
Armstrong, Cheryl, M.
Reed, Sue, A.
Berger, Bryan
Abstract
Provided herein are compositions and methodologies for identifying microbes in biofilms and adhered to biotic and abiotic surfaces, utilizing enzymes that degrade biofilms and disperse aggregated clusters of microorganisms. Utilizing enzymes such as CAase to degrade biofilms, organisms released from biofilms are identified more readily than from untreated biofilms. Biofilms from a variety of sources, both biotic and abiotic, can be analyzed utilizing the present disclosure.
C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
30.
COMPOSITIONS COMPRISING LINEAR, STAR-SHAPED, AND COMB-LIKE STAPLED P9-PEG CONJUGATES AND METHODS OF USE THEREOF
Provided are stapled peptides and conjugates thereof that have antibacterial activity against microbial pathogens that include, but are not limited to, multidrug-resistant bacteria. Also provided are stapled peptides and conjugates thereof that are functionalized, encapsulated in a particle, and/or embedded in and/or on a solid support, optionally wherein the stapled peptide and/or conjugate is formulated for release from the solid support, impregnated in a dressing, optionally wherein the stapled peptide and/or conjugate thereof is formulated for release from the dressing, medical devices having a support layer with an antibacterial agent embedded therein or associated therewith, and methods for inhibiting the growth of and/or killing microbes.
C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides
A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
Provided are polypeptides that have at least about 95% but less than 100% sequence identity to SEQ ID NO: 2, optionally wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO: 4, with the proviso that the polypeptide does not have 100% sequence identity to SEQ ID NO: 2. Also provided are polypeptides that include an amino acid sequence that is a variant of SEQ ID NO: 2, wherein the variant sequence has at least one substitution at an amino acid position selected from the group consisting of D287, D291, D311, N313, D315, L307, and N284 of SEQ ID NO: 2; optionally wherein the polypeptide inhibits growth of a microbe and/or microbial biofilm and/or disrupts a microbial biofilm; nucleic acid molecules encoding the disclosed polypeptides; vectors and recombinant host cells that include the disclosed nucleic acid molecules; antimicrobial compositions that include an effective amount of the disclosed polypeptides, optionally that also include a carrier and/or one or more additional active agents; and methods for inhibiting the growth of microbes and/or microbial biofilms on surfaces and/or for disrupting microbial biofilms on surfaces and methods for inhibiting the growth of microbes on and/or in agricultural products and/or subjects.
A61L 2/16 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
32.
METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR CGM-BASED PREVENTION OF HYPOGLYCEMIA VIA HYPOGLYCEMIA RISK ASSESSMENT AND SMOOTH REDUCTION INSULIN DELIVERY
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
33.
METHOD AND SYSTEM OF CLOSED LOOP CONTROL IMPROVING GLYCEMIC RESPONSE FOLLOWING AN UNANNOUNCED SOURCE OF GLYCEMIC FLUCTUATION
A method, system, and computer-readable medium are provided for a dual mode Closed-Loop Control (CLC) system integrating each of (i) an adaptive, personalized Model Predictive Control (MPC) control law that modulates the control strength of insulin infusion depending on recent past control actions, glucose measurements, and their derivative(s), (ii) an automatic Bolus Priming System (BPS) that commands additional insulin injections upon the detection of enabling metabolic conditions (e.g., an unannounced meal), and (iii) a hyperglycemia mitigation system (HMS) to avoid prevailing hyperglycemia.
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
The present disclosure relates to compositions and methods related to tissue-specific promoters and their uses in plants, including tobacco and Cannabis. The provided trichome-specific promoters enable the expression of heterologous polynucleotides in trichome tissues.
The invention relates to a methods and systems for determining an insulin dosing recommendation. The invention employs Linear Quadratic methodology to determine the insulin dosing recommendation based on a patient's present physiological state, which is estimated by an adaptive filter methodology employing a dynamic model, which utilizes real-time measurements of blood glucose concentration.
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
G16Z 99/00 - Subject matter not provided for in other main groups of this subclass
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
36.
COMPOSITIONS AND RELATED METHODS FOR MODULATING ALKALOID PRODUCTION BY CONTROLLING PMT PROMOTER ACTIVATION MEDIATED BY TRANSCRIPTIONAL FACTORS ERF AND MYC
Compositions and methods for modifying the production levels of alkaloids in plants are provided. Alkaloid production can be genetically controlled by modulating the transcriptional activation of PMT genes mediated by members of the ERF family and/or Myc family of transcription factors. Novel nucleotide sequences encoding the Myc family of transcription factors are also provided.
C07C 67/04 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides onto unsaturated carbon-to-carbon bonds
C07C 69/22 - Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
38.
BIOMIMETIC TORPEDO FOR STENT-FREE AND TARGETED GENE THERAPY TO PREVENT RESTENOSIS
Disclosed herein is a biomimetic torpedo that can circumvent existing hurdles for RNA therapies. That is, RNA therapeutics can be harbored inside a torpedo shell made of neutrophil membranes in hybrid with a liposome membrane, which enables lesiontargeting and shielding from immunogenicity. Further disclosed herein is a biomimetic targeting system that involves a neutrophil cell membrane capsule that encapsulates a therapeutic RNA.
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61K 47/42 - Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
The present disclosure provides for methods of making graphene, systems for making graphene and graphene produced from the methods and systems. Biomass materials, such as cotton materials, can be converted to graphite and then the graphite is converted into graphene. One method of the present disclosure can include removing substances from the biomass material, carbonization, graphitization, and exfoliation.
B01J 19/10 - Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor employing sonic or ultrasonic vibrations
40.
USE OF LASERS TO SELECTIVELY REMOVE MATERIALS FROM SUBSTRATES
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein are methods for selectively removing a material from a surface of a substrate. The method involves applying a laser to the material to remove the material from the substrate. The laser thermally vaporizes the material or de-bonds the material from the substrate to produce particles, and the material particles can be subsequently removed and re-used in subsequent applications. The methods described herein provide an efficient process for removing materials from substrates that would otherwise be discarded.
B23K 26/122 - Working by laser beam, e.g. welding, cutting or boring in a special environment or atmosphere, e.g. in an enclosure in a liquid, e.g. underwater
B23K 26/082 - Scanning systems, i.e. devices involving movement of the laser beam relative to the laser head
B23K 26/16 - Removal of by-products, e.g. particles or vapours produced during treatment of a workpiece
B23K 26/50 - Working by transmitting the laser beam through or within the workpiece
C04B 41/91 - After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone of only ceramics involving the removal of part of the materials of the treated articles, e.g. etching
H01L 27/14 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including semiconductor components sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy
41.
MICROTEXTURIZED SUBSTRATES AND METHODS FOR PRODUCING THE SAME
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to methods for producing a microtextured surface on a substrate. The method involves the surface of the substrate to a pulsed laser across the substrate at a controlled overlap of each pulsed laser to produce the microtextured surface. The morphology of the microtextured surface can be varied by controlling the laser processing parameters. The microtextured surfaces produced by the methods described herein possess a significantly higher adhesion strength to surface coatings such as, for example, metal coatings when compared to conventional texturizing techniques.
A multicompartment conductive collagen scaffold composite, comprising a scaffold comprising collagen and an electrically conductive material, optionally wherein the electrically conductive material comprises electrically conductive particles, and further comprising longitudinally aligned pores, and methods of making and using the same.
Compositions for identifying a pathogenic bacterial infection include a mannitol compound with one or more substituents including radioisotopes. These radiopharmaceuticals, such as a positron- emitting mannitol analogue, [18F]fluoromannitol ([18A. baumanniiS. epidermisP.mirabilisS. entericaK. pneumonia,E. faecium E. cloacaeM. marinumM. marinum, but not non-active infection sites such as sterile inflammatory sites, cancer sites, etc. Administration of these radiopharmaceuticals to and subsequent imaging of patients, e.g., via positron emission tomography (PET), enables detection of deep-seated and difficult to manage bacterial infections, such as osteomyelitis and prosthetic joint infection, or in patients with sickle cell disease. [18F]FMtl injection detects and differentiates infection rapidly. The radiolabeled mannitol compounds can be produced via nucleophilic substitution reactions that are deployable on commercially available synthesizers, facilitating straightforward and wide accessibility, and counteracting unnecessary antibiotic use.
In one aspect, the disclosure relates to methods for producing hydrophobic or superhydrophobic surfaces on an article. The method involves laser depositing hydrophobic materials on at least one surface of the article. By varying the laser parameters as well as the surface of the where the hydrophobic material is to be laser deposited, the hydrophobic properties of the surface can be modified. The starting substrate could be hydrophilic or superhydrophilic.
C03C 17/30 - Surface treatment of glass, e.g. of devitrified glass, not in the form of fibres or filaments, by coating with organic material with silicon-containing compounds
C03C 17/28 - Surface treatment of glass, e.g. of devitrified glass, not in the form of fibres or filaments, by coating with organic material
C09D 5/00 - Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
A technique for automated classification of biological subpopulations can include or use training a classifier by receiving an analyte biological specimen defining biophysical features characterized by corresponding electrical impedance parameters, within a test cell through which the biological specimen is flowing, measuring an electrical impedance of the biological specimen using a specified range of frequencies, extracting at least two electrical impedance parameters from the measured electrical impedance, and using the at least two electrical impedance parameters as an input to a trained classifier, training the classifier using training data from a plurality of other biological specimens and corresponding electrical impedance parameters of such training data.
Compositions, foodstuff and methods are provide herein from cereal plant or a part thereof, wherein the plant or part thereof has an altered (I,3;l,4)-p-glucan content as compared to a wild-type cereal plant or part thereof, wherein said, plant or part thereof carries one or more mutations in the CslF6 gene, wherein said mutated. CslF6 gene encodes a mutant CslF6 polypeptide, wherein said mutant CslF6 comprises at least one substitution, addition or deletion of an amino acid in a switch motif of CslF6, wherein the switch motif comprises SEQ ID NO: 14.
A microfluidic system can be used to quantify apoptotic bodies (ABs) with single-cell sensitivity, providing real-time information regarding the presence, and properties of ABs. Different subpopulations of ABs can thus be distinguished from one another to quantify cellular dis-assembly and drug sensitivity of the cancer cells under test. Impedance measurement can be performed by flowing secreted bodies at a substantially single-particle sensitivity. A plurality of electrical impedance magnitude and phase parameters of the biological sample can be measured within the flow cell structure, corresponding to a specified range of frequencies to help determine a biological characteristic of the cancer cells.
Disclosed herein are systems, methods, and computer-readable media for sorting datasets within a Processing in Memory (PIM)-based system. A request to sort a dataset stored in a 3D-stacked memory can be received. The request can identify a specific dataset and sorting criteria, which includes a plurality of keys. The dataset can be partitioned into several subarrays across various memory banks within the 3D-stacked memory. Each piece of data within these subarrays can be separated into buckets based on the keys. Local histograms for each subarray and bank histograms based on the local histograms can be generated. A prefix-sum operation on the bank histograms can determine individual positions for the sorted dataset. Aggregation of the subarrays from all memory banks can form the sorted dataset, which can be subsequently returned.
G06F 7/26 - Sorting, i.e. extracting data from one or more carriers, re-arranging the data in numerical or other ordered sequence, and re-recording the sorted data on the original carrier or on a different carrier or set of carriers the sorted data being recorded on the original record carrier within the same space in which the data had been recorded prior to their sorting, without using intermediate storage
G06F 7/49 - Computations with a radix, other than binary, 8, 16 or decimal, e.g. ternary, negative or imaginary radices, mixed radix
49.
AUTOMATED CELL CULTURING AND CHARACTERIZATION TO RESEMBLE IN VIVO CONDITIONS
A method of automated cell culturing and characterization can include regulating one or more parameters of an ambient environment within an environmentally isolated, airtight enclosure. A biological specimen can be cultured within the enclosure, e.g., including aspirating and dispensing, via an automated fluid handling system having a fluidic interface disposed within the airtight enclosure, a portion of the biological specimen. The dispensing can be into a first vessel, e.g., by suspending individual cells of the portion of the biological specimen within a microcarrier matrix contained by the first vessel and exposed to the ambient environment within the airtight enclosure.
Provided are methods for treating tumors and/or cancers in subjects in need thereof. In some embodiments, the method include administering to the subject an inhibitor of a Rho-Associated Coiled-Coil Containing Protein Kinase 1 (ROCK1) 5 biological activity and/or a checkpoint inhibitor. In some embodiments, the cancer is a solid tumor. Also provided are compositions that have an effective amount of an inhibitor of a Rho-Associated Coiled-Coil Containing Protein Kinase 1 (ROCK1) biological activity and/or an effective amount of a checkpoint inhibitor; and an effective amount of a DR5 agonist, which can be a bispecific antibody; bispecific antibodies that has a first antigen binding site that is specific for the DRS polypeptide and a second antigen binding site that is specific for the ROCK1 polypeptide, the CTLA4 polypeptide, the PD-1 polypeptide, or the PD-L1 polypeptide; compositions for use in treating tumors and/or cancers, including bispecific antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
An image calibration method includes capturing and correcting a flood field image for background signal and effects of known image-panel features (dead/bad pixels). The corrected image is processed to separate frequencies characteristic of relative pixel sensitivities from frequencies characteristic of radiation energy fluence. The incident energy fluence has a known maximum in-field energy fluence gradient. A model that describes the incident energy fluence on a detector is generated or received. The corrected image may be modeled at frequencies at or below the maximum in-field energy fluence gradient. A pixel sensitivity matrix (PSM) is generated by adjusting the corrected image with the model of the incident energy fluence on the detector. For example, the corrected image signal may be divided by the model or the model may be subtracted from the corrected image. The PSM may be used to correct additional raw images captured by the detector.
Embodiments relate to a database management system for efficient physiological diagnosis of a specified physiological disorder. The system includes a physical data store containing glucose measurement data and a representation for a classification of the glucose measurement data. The glucose measurement data is associated with controlled glycemic-response consumption activity, the representation being indication that a glucose measurement trace is associated of a specified physiological disorder or is indicative of the specified physiological disorder, or is a surrogate of an existing metabolic test, e.g. OGTT. A processor receives a new glucose measurement possibly associated with controlled glycemic-response consumption activity, and classifies the newly received glucose measurement trace with the representation based either on a disease- or test-specific classifier or based on a matched similarity metric, and ascribes a clinical recommendation or assessment based on the representation of the classified newly received glucose measurement trace.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
A method and system are disclosed for efficient early detection of co-evolutionary sites among genomic sequences. Exemplary embodiments extract/approximate a data motif complex of a given data set wherein the extraction procedure can be performed using at least two steps. One step is construction of a vertex set of the data motif complex by identifying data sites with high informational variation. Another step is construction of higher dimensional simplices which systematically represent informational patterns within the data set. The method and system can be implemented as a computer-implemented software pipeline as described herein. An exemplary application can rapidly recognize key or critical mutational blocks in viral SARS-CoV-2 genomic data.
Rolls-Royce North American Technologies Inc. (USA)
University of Virginia Patent Foundation (USA)
Inventor
Connolly, Brian J.
Loth, Eric
Smith, Iii, Crawford F.
Abstract
An inlet duct for a gas turbine engine includes a particle separator, a scavenge duct, and a layer of material having a low coefficient of restitution. The particle separator including an outer wall spaced, an inner wall, and a splitter located radially between the outer wall and the inner wall. The scavenge duct is coupled with particle separator. The layer of material is located on at least one of the outer wall, the splitter, and the scavenge duct.
F02C 7/052 - Air intakes for gas-turbine plants or jet-propulsion plants having provisions for obviating the penetration of damaging objects or particles with dust-separation devices
55.
METHOD AND SYSTEM FOR LOW-FIELD MRI DENOISING WITH A DEEP COMPLEX-VALUED CONVOLUTIONAL NEURAL NETWORK
Blurring and noise artifacts in magnetic resonance (MR) images caused by off-resonant image components may be corrected with convolutional neural networks, particularly feed forward networks with skip connections. Demodulating complex blurred images with off-resonant artifacts at a selected number of frequencies forms a respective real component frame of the MR data and a respective imaginary component frame for each image. A convolutional neural network is used to de-blur the images. The network has a plurality of residual blocks with multiple convolution calculations paired with respective skip connections. The method outputs, from the convolutional neural network, a de-blurred real image frame and a de-blurred imaginary image frame of the MR data for each complex blurred image.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
Embodiments of the present disclosure include a walker equipped with one or more sensors, an onboard controller, powered wheels and associated motor controllers. The walker can sense its distance from the user and activate the powered wheels when commanded by the controller. The controller can execute programming including an automatic feedback control algorithm that regulates the distance between the walker frame and the user. In this manner, the walker automatically follows the user, keeping the user from having to expend energy to pull the walker along. The walker can then be utilized by the user solely for balance and support.
Disclosed herein is a Dynamic Random Access Memory-Based Content-Addressable Memory (DRAM-CAM) architecture and methods relating thereto. The DRAM-CAM architecture can include a memory array, with the data organized into blocks including rows and columns. Input data can be converted into a format with first and second groups of columns. Each first group can correspond to one or more rows of the input data, and each second group can include one or more null columns. A query can be received and loaded into an available column of the second group, and pattern matching can be performed on the data to identify occurrences of elements defined by the query. The pattern matching can be performed concurrently on the first groups of columns and the available columns bit by bit. Results can include a count or location of each identified element.
According to some embodiments, a linear-reversible-linear (LRL) copolymer may comprise an A(BC)A triblock copolymer. The A(BC)A triblock copolymer may comprise an A block and a BC block. The A block may a linear polymer and the BC block may comprises a copolymer with the ability to form reversible bonds. Further embodiments include methods of making and methods of using the LRL copolymer.
C08F 220/18 - Esters of monohydric alcohols or phenols of phenols or of alcohols containing two or more carbon atoms with acrylic or methacrylic acids
C08F 293/00 - Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
59.
INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY
The present disclosure provides SPNS2 inhibitor compounds according to Formula (I) and their pharmaceutically acceptable salts, and/or tautomers as described in the disclosure, and the disclosure provides their pharmaceutical compositions and methods of use in therapy.
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
A damping mechanism for damping energy resulting from a lateral force on a structure may include a first portion, a second portion configured for longitudinal motion relative to the first portion, a primary energy absorption system configured for frictionally coupling the first portion and the second portion and converting motion of the second portion relative to the first portion into heat energy, and a secondary energy absorption system configured to absorb energy through non-linear deformation and provide a self-centering effect on the damping mechanism.
E04H 9/02 - Buildings, groups of buildings or shelters adapted to withstand or provide protection against abnormal external influences, e.g. war-like action, earthquake or extreme climate withstanding earthquake or sinking of ground
F16F 7/08 - Vibration-dampers; Shock-absorbers with friction surfaces rectilinearly movable along each other
F16F 7/12 - Vibration-dampers; Shock-absorbers using plastic deformation of members
61.
METHOD AND SYSTEM FOR ALL-AQUEOUS PRINTING OF VISCOELASTIC DROPLETS
This document describes printing viscoelastic material in an aqueous medium. Such printing can involve positioning a print nozzle at specified coordinates in the medium and triggering deposition of the viscoelastic material to form a viscoelastic droplet. The deposition can be established by delivering a specified flow velocity of the viscoelastic material through an aperture in the print nozzle. The print nozzle can be detached from the droplet and a receiving material by translating the nozzle relative to the droplet according to a specified acceleration. The droplet can remain captive on or within the receiving material upon detachment from the nozzle.
B33Y 30/00 - ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING - Details thereof or accessories therefor
62.
THERAPEUTIC TARGETING OF ACTIVATED AVIL-INDUCED SARCOMAS
Disclosed herein are silencing oligonucleotides useful to regulate, limit, or inhibit the expression of AVIL (advillin). Also disclosed herein are methods for treating disorders associated with AVIL dysregulation using same. In some embodiments, the method involves treating a cancer, such as glioblastomas, rhabdosarcomas, gliomas, lung cancer, bladder cancer, or renal cancer.
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61P 35/04 - Antineoplastic agents specific for metastasis
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
63.
SYSTEM COORDINATOR AND MODULAR ARCHITECTURE FOR OPEN-LOOP AND CLOSED-LOOP CONTROL OF DIABETES
A structure, method, and computer program product for a diabetes control system provides, but is not limited thereto, the following: open-loop or closed-loop control of diabetes that adapts to individual physiologic characteristics and to the behavioral profile of each person. An exemplary aspect to this adaptation is biosystem (patient or subject) observation and modular control. Consequently, established is the fundamental architecture and the principal components for a modular system, which may include algorithmic observers of patients' behavior and metabolic state, as well as interacting control modules responsible for basal rate, insulin boluses, and hypoglycemia prevention.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
64.
HERMETICALLY OR ASEPTICALLY SEALED BIOREACTOR SYSTEM AND RELATED METHOD THEREOF
Disclosed herein are details of a hermetically or aseptically sealed bioreactor. The bioreactor comprises a bioreactor chamber, a membrane wall, a scaffold structure, a linear actuator, a linear transfer means, and a control system. Use of the bioreactor permits the inner scaffold structure to be moved and manipulated while still preserving a hermetic or aseptic seal inside the bioreactor chamber during operation.
Provided are methods for treating macular degeneration, optionally macular degeneration, in subject in need thereof. In some embodiments, the methods include administering to a subject in need thereof a therapeutically effective amount of fluoxetine in an amount and via a route sufficient to treat or prevent development of macular degeneration in the subjects. Also provided are methods for inhibiting activation of an NLRP3-ASC inflammasome in the subjects, inhibiting ASC speck formation in the subjects, inhibiting Alu RNA-induced RPE degeneration in the subjects, and treatment and/or prevention of the development of diseases, disorders, and/ or conditions.
The presently disclosed subject matter provides devices, systems, and methods for model inter-organ communication. In some embodiments, a multi-organ-on-a-chip (MOC) system can include one or more micro-culture well configured to receive a live tissue sample therein and an impeller-based pump in fluid communication with the one or more micro-culture well. In this arrangement, the impeller-based pump can be configured to generate fluid flow through the one or more micro-culture well.
Disclosed herein are processes term Bacterial Chloro-Alkane Penetration Assay (BaCAPA) and Bacterial Azide Permeability Assay (BAPA) The processes employ a genetically encoded protein called HaloTag to measure the uptake and accumulation of molecules into Gram-negative bacteria. The processes aqre useful in assessing the permeation of molecules within the phagocytes of macrophages, and they effectively report on the accumulation of molecules into bacterial cells, thereby identifying potential antibiotic drugs.
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
C12Q 1/18 - Testing for antimicrobial activity of a material
C12Q 1/25 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups
68.
Method and System for Generating a User Tunable Representation of Glucose Homeostasis in Type 1 Diabetes Based on Automated Receipt of Therapy Profile Data
A method, system, and computer-readable medium are provided for modeling a time-varying representation of the glucose homeostasis of a patient with Type 1 diabetes (T1D) according to a computational model therefor. The model implements a reconstruction of data supporting a glucose time series for the patient, and based on the reconstruction, further implements model personalization and a variability control (VC) signal accounting for insulin sensitivity so as to enable the patient to learn an effect of adjustment to one or more portions of the data. Such knowledge is acquired upon a replay of the reconstruction implementing the adjustment.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
69.
DEVELOPMENT OF NANO-ENCAPSULATED FATTY-ACYL CONJUGATED COLCHICINE
Provided are compositions that include colchicine conjugated to behenic acid, optionally wherein the colchicine conjugated to behenic acid is encapsulated by a nanoliposome. In some embodiments, the colchicine is conjugated to behenic acid at the acetamide position of a B-ring of colchicine, the nanoliposome includes a lipid component comprising DSPC, DOPE, and DSPE-PEG, and cholesterol; and/or the colchicine conjugated to behenic acid is present in the nanoliposome in an amount of at least about 400, 500, 600, or more than 600 pg/mL. Also provided are methods for preparing behenic acid-conjugated colchicine derivatives, methods for preparing lipid nanoparticle-encapsulated colchicine derivatives, and methods for using the same to treat and/or prevent inflammatory and/or cardiovascular diseases, disorders, and/or conditions.
Provided are compositions that include compositions of galactosyl-conjugated lipid, nanoparticles (LNPs) encapsulating one or more active agents. In some embodiments, the galactosyl-conjugated LNPs have a lipid component having D-Lin-MC3 -DMA, ALC-0315 and SM-102, cholesterol, DSPC and DOPE, and DMG-2000-PEG. In some embodiments, the GalN Ac-conjugated LNP has one or more galactosyl moieties bioconjugated to cholesterol present with a lipid component of the GalNAc-conjugated LNP. Also provided are methods for treating and/or preventing diseases, disorders, and/or conditions associated with undesirable gene expression and methods for targeting active agents to hepatocytes using the presently disclosed GalN Ac-conjugated LNPs.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
71.
SYSTEM AND METHOD FOR IDENTIFYING CLINICALLY-SIMILAR CLUSTERS OF DAILY CONTINUOUS GLUCOSE MONITORING (CGM) PROFILES
Embodiments relate to a system for processing glucose data by efficient glucose database management. The system includes a physical data store containing glucose measurement data and a representation for at least one cluster of the glucose measurement data, wherein the representation approximates a glycemic profile vector array for a cluster of multiple glucose profiles segmented by plural time ranges. The system includes a processor and computer memory configured with instructions stored thereon that when executed will cause the processor to: 1) receive glucose measurements; 2) convert the glucose measurements into vectorial form; 3) search the physical data store by comparing a newly received glucose measurement to a centroid of a cluster using a similarity metric; 3) classify the newly received glucose measurement with a cluster having a matched similarity metric based on the comparing; and 4) ascribe a treatment to the newly received glucose measurement.
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
An integrated circuit memory device can include a plurality of banks of memory, each of the banks of memory including a first pair of sub-arrays comprising first and second sub-arrays, the first pair of sub-arrays configured to store data in memory cells of the first pair of sub-arrays, a first row buffer memory circuit located in the integrated circuit memory device adjacent to the first pair of sub-arrays and configured to store first row data received from the first pair of sub-arrays and configured to transfer the row data into and/or out of the first row buffer memory circuit, and a first sub-array level processor circuit in the integrated circuit memory device adjacent to the first pair of sub-arrays and operatively coupled to the first row data, wherein the first sub-array level processor circuit is configured to perform column oriented processing a sparse matrix kernel stored, at least in-part, in the first pair of sub-arrays, with input vector values stored, at least in part, in the first pair of sub-arrays to provide output vector values representing products of values stored in columns of the sparse matrix kernel with the input vector values.
Provided are composition that include stable TLR4 agonist (e.g., KDO2) containing nanoliposomes. In some embodiments, the TLR4 agonist (e.g., KDO2) containing nanoliposome include a lipid component comprising, consisting essentially of, or consisting of DSPC, DOPE, PEG(2000)-PE, one or more TLR4 agonists (e.g., KDO2), Cholesterol, Rhodamine or DiD, and optionally DOTAP and/or DHP. In some embodiments, the TLR4 agonist (e.g., KDO2) containing nanoliposomes are cationic, anionic, or neutral liposomes. In some embodiments, the TLR4 agonist (e.g., KDO2) containing nanoliposome encapsulate one or more immunogenic peptides, which can be peptides associated with malignant melanoma, which optionally can be subsequences of tyrosinase, gplOO, MAGE-1,2,3,6, Melan-A/MART- 1, and/or MAGE-3. Also provided are methods for treating and/or preventing malignant melanoma and for inducing anti-melanoma immune responses in subjects using the presently disclosed compositions.
Systems and methods are disclosed for generating cluster quantum states usable for quantum computing. An example system can generate a plurality of qumodes. The plurality of qumodes can include at least two successive qumodes in frequency domain, wherein a frequency spacing between two successive qumodes is equal to a free-spectral range of an optical frequency comb. The plurality of qumodes can include a plurality of bipartite entangled states. A cluster quantum state can be generated by modulating a phase of a portion of the optical fields associated with the plurality of qumodes received from the optical frequency comb, at one or more modulation frequencies. In some embodiments, each of the one or more modulation frequencies can be equal to an integral multiple of the free-spectral-range. In certain embodiments, a property of a cluster graph (such as a dimension of the cluster graph) associated with the cluster quantum state can be controlled by adjusting one or more modulation frequencies.
MR image data can be improved by using a complex de-noising convolutional neural network such as a non-blind C-DnCNN, a network for MRI denoising that leverages complex-valued data with phase information and noise level information to improve denoising performance in various settings. The proposed method achieved superior performance on both simulated and in vivo testing data compared to other algorithms. The utilization of complex-valued operations allows the network to better exploit the complex-valued MRI data and preserve the phase information. The MR image data is subject to complex de-noising operations directly and simultaneously on both real and imaginary parts of the image data. Complex and real values are also utilized for block normalization and rectified linear units applied to the noisy image data. A residual image is predicted by the C-DnCNN and a clean MR image is available for extraction.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
An apparatus related method for measuring a property of a target material. The system may include a pump device that generates a pump beam. A modulation device may receive the pump beam and generate a modulated pump beam by modulating an intensity amplitude of the pump beam, which may be directed to the target material. A probe device may generate a probe beam, which is directed to the target material. A part of the probe beam may be reflected off of the target material, and has similar frequency characteristic as the modulated pump beam. A detection device may detect the reflected probe beam and produce a signal. An analyzing device may receive the signal and calculate the target material property by comparing the modulated frequency characteristics of the signal to those of the pump beam. At least one of the pump and the probe beams may be infrared light.
The present disclosure provides SPNS2 inhibitor compounds according to Formula (IA) and Formula (I), and their pharmaceutically acceptable salts, and/or tautomers as described in the disclosure, and the disclosure provides their pharmaceutical compositions and methods of use in therapy.
C07C 225/10 - Compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly-bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings with doubly-bound oxygen atoms bound to carbon atoms not being part of rings
C07D 263/58 - Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 211/34 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
80.
AUTOMATION OF THE BLOOD INPUT FUNCTION COMPUTATION PIPELINE FOR DYNAMIC FDG PET FOR HUMAN BRAIN USING MACHINE LEARNING
In some examples, method for automatically computing a blood input function for dynamic positron emission tomography (PET) includes obtaining dynamic PET image data sets comprising volumetric radioactive measurement data associated with an administered radioactive tracer present in a target site of a subject over multiple scanning intervals. The method includes utilizing an artificial neural network (ANN) to segment the dynamic PET image data sets displaying one or more blood vessels in the target site. The method includes automatically deriving, using the ANN, a blood input function ( I D I F) based on radioactive tracer concentrations measured in one or more segments of the plurality of dynamic PET image data sets. The method includes computing a predictive model-corrected blood input function (MCIF) using time activity curve input associated with the automatically derived IDIF.
A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G06N 3/0442 - Recurrent networks, e.g. Hopfield networks characterised by memory or gating, e.g. long short-term memory [LSTM] or gated recurrent units [GRU]
Boronated prodrugs have been developed that are particularly advantageous for use in boron proton capture therapy (BPCT) and boron neutron capture therapy (BNCT). Cancer-targeting moieties, such as heptamethine cyanine dyes (HMCDs), are linked to compounds including a plurality of boron isotopes, e.g., carboranes such as 1 -amino- 1-carbadodecaborate. Compounds of the present disclosure were demonstrated to deliver eleven boron-11 atoms per dye molecule selectively to breast cancer cells. Upon irradiation with proton or neutron beams and subsequent nuclear fusion reaction by proton capture, unstable 12C is generated in place of 11B, which is short lived and releases high energy alpha particles. There particles travel only a short distance within cell and/or a very close tumor microenvironment, damaging cellular DNA ultimately resulting in killing cancer cells, and are particularly useful with young patients and with deep tissue tumors located in critical organs which are difficult to remove by surgery.
Provided are compositions and methods for treating cancer and mimicking oxidative stress in a subject. In some embodiments, the methods include modulating vascular oxidative stress, inflammation, and/or hypertension in a subject. Also provided are methods for evaluating therapeutic compositions in a subject with modulated vascular oxidative stress, inflammation, and/or hypertension.
The present invention provides novel bispecific antibodies that bind to human CD30 and uses thereof. Methods of treating cancer using the bispecific antibodies described herein are also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are methods for identifying subjects at risk for reduced lifespan, age- associated cardiomyopathy, reduced cardiac function, heart failure, increased fibrosis of the myocardium, lung, and/or kidney; idiopathic pulmonary fibrosis (IPF); elevated left ventricular filling pressure (E/e') indicative of diastolic dysfunction; and/or reduced cognitive function. In some embodiments, the methods include determining if the subject has mosaic loss of chromosome Y in blood (mLOY). Also provided are methods for preventing and/or treating diseases, disorders, and/or conditions associated with mLOY, which in some embodiments also include administering an anti-fibrotic therapy to the subject. Also provided are uses of inhibitors of TGF0 signaling or senolytic agents for prevention and/or treatment of diseases, disorders, and/or conditions associated with mLOY.
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
C12Q 1/6865 - Promoter-based amplification, e.g. nucleic acid sequence-based amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]
C12Q 1/6879 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for sex determination
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
85.
DELIVERY OF DISSOCIATED ISLETS CELLS WITHIN MICROPOROUS ANNEALED PARTICLE SCAFFOLD TO TREAT TYPE 1 DIABETES
Provided are compositions that include single cell suspensions of pancreatic islet cells, pancreatic islet-like cells derived from iPS cells, or combinations thereof, wherein the cells are present within a MAP scaffold and/or are encapsulated by MAPs. In some embodiments, the MAP scaffold and/the MAPs have a polymer backbone that includes poly(ethyleneglycol) (PEG), hyaluronic acid, polyacrylamide, polymethacrylate, alginate, collagen, or any combination thereof. Also provided are methods for using the presently disclosed compositions for treating Type 1 diabetes, for example by administering to a subject with Type 1 diabetes such a composition via a route and in an amount effective for treating the Type 1 diabetes in the subject. In some embodiments, the administering includes injecting the composition into a kidney capsule, subcutaneously, intraperitoneally, into adipose tissue, intramuscularly, intrahepatically, and/or intrapancreatically into the subject.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
The invention relates to inhibitors of EWS-FLI1, pharmaceutical compositions containing the inhibitors, and methods of treating cancer, including Ewing sarcoma, leukemia, diffuse large B-cell lymphoma (DLBCL), and prostate cancer, comprising the administration of the inhibitors and pharmaceutical compositions thereof.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61P 35/02 - Antineoplastic agents specific for leukemia
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
88.
METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR CGM-BASED PREVENTION OF HYPOGLYCEMIA VIA HYPOGLYCEMIA RISK ASSESSMENT AND SMOOTH REDUCTION INSULIN DELIVERY
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
89.
COMBINATION SODIUM-GLUCOSE COTRANSPORTER INHIBITOR (SGLTI)- INSULIN THERAPY FOR GLYCEMIC CONTROL IN TYPE 1 DIABETES
Provided are a method, system, and computer-readable medium for optimizing glycemic control of a diabetic subject having Type 1 diabetes through co-administration of sodium-glucose cotransporter inhibitors (SGLTi) and insulin. Such co-administration can be effected by, for example, regulating one or more administration reactions in view of analyses of continuous glucose monitoring (CGM) data that can be indicative of at least the potential for one or more glycemic events including hypoglycemia and hyperglycemia. The aforementioned regulation can occur according to a balancing of insulin infusion and provisioning of SGLTi so as to avoid the occurrence of either of such events while, at the same time, not promoting an instance of diabetic ketoacidosis (DKA).
Disclosed are compositions and methods for treating a disease and/or disorder such as cancer in a subject in need thereof. In some embodiments, the method includes administering to the subject a nucleic acid construct that includes a first nucleic acid sequence having a promoter operably linked to each of a second nucleic acid sequence encoding a therapeutic polypeptide, and a third nucleic acid sequence encoding a peptide domain that is stabilized when phosphorylated by stress-activated kinase activity in a target cell and/or tissue. In some embodiments, the target cell and/or tissue is a cell and/or tissue undergoing a stress response. In some embodiments, the kinase activity is stress-activated kinase activity mediated by p38/MAP14 kinase activity, INK activity, or both.
A method for quantifying bacterial spore germination can include creating an ex vivo assay including bacteria spores and a homogenized stool sample. The ex vivo assay can be loaded into a microfluidic chip. Vegetative bacteria and the bacteria spores can be detected by sampling the mixture in the microfluidic chip using impedance cytometry to assess disruption of host microbiota.
C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
Hepatocellular cancer (HCC) is the most common primary hepatic malignancy and is the third-highest cause of cancer-related death. Surgical resection and liver transplantation are curative treatments for only a small number of early-stage patients. Disclosed are compositions and methods of treating hepatocellular cancer. The compositions include a combination therapy including nanoliposome C6-cerarnide and anticytotoxic T-lymphocyte antigen 4 antibody.
A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
Systems and methods for 3D bioprinting of hydrogel voxels enable microfluidics-assisted digital assembly of spherical particles (DASP). The systems include a 3D motion system, a microfluidic printhead coupled to the 3D motion system, an extrusion device fluidly coupled to the microfluidic printhead, and a sacrificial support matrix. The sacrificial support matrix is designed to support the hydrogel voxels during printing and cross-link the hydrogel voxels. The system includes bio-inks comprising hydrogel compositions having independently controllable viscoelasticity and mesh size. The bio-inks are extruded by the extrusion device and microfluidic printhead to produce the hydrogel voxels. Exploiting the microfluidic printhead enables printing individual spherical hydrogel voxels with diameters from 150 micrometers (μm) to 1200 μm. Positioning and interconnection of the hydrogel voxels can be precisely controlled. The systems and methods produce free-standing 3D structures and can be used for producing functional tissue mimics.
Methods for sensitizing tumors and/or cancers in subjects to therapeutic agents are provided. In some embodiments, the methods include administering to the subject one or more compositions that include an effective amount of an inhibitor of TRIM37 activity. Also provided are methods for sensitizing tumors and/or cancers in subjects to therapeutic agents by administering to the subjects one or more compositions that include an effective amount of an inhibitor of TRIM37 activity and purified and isolated antibodies and fragments thereof that have at least one paratope and further have a linker sequence through which the antibody can be conjugated to a carrier in which the linker sequence includes the amino acid sequence ((X)3Cys(X)3, wherein each X is independently any amino acid.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Methods for treating coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, are described. The methods include administration of combinations of agents, including combinations that include dupilumab. The methods can be used to treat subjects diagnosed with a SARS-CoV-2 infection, including those already hospitalized to treat COVID-19 and/or those also having lymphopenia, to reduce the severity of outcomes related to COVID-19, such as admittance to the intensive care unit (ICU), mechanical ventilation, and/or death, particularly over periods of time longer than a month or two months following the initial administration of the agents. Compositions for use in the treatment of COVID-19 are also described.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
97.
INWARD FLUID DISPLACEMENT (IFD) IN ROTATIONAL MICROFLUIDIC DEVICE
Apparatus and techniques described herein can include or use a rotationally-driven microfluidic assembly. For example, a sample can be propelled to a sample recovery chamber from a sample chamber using a gas evolved from a reaction between the liquid reagent and a dry reagent. Such gas evolution can provide displacement of a sample liquid or other liquid in an inward direction, such as proximally toward a center of rotation. Such gas evolution can include features or reagents, or both, that are compatible with downstream nucleic acid amplification tests.
Provided are methods and compositions for treating and/or preventing C. difficile infections, particularly recurring C. difficile infections. The compositions for use in treating and/or preventing C. difficile infections include in some embodiments at least one agent that inhibits an alpha 2 adrenergic receptor, and the presently disclosed methods include administering at least one such composition to a subject in need thereof, optionally in combination with other therapeutically active agents including but not limited to an enhancer of an IL-13 biological activity, optionally an IL-13 peptide or a fragment or homolog thereof; an interleukin-13 receptor subunit alpha-2 (IL-13Ra2) inhibitor; an enhancer of an Interleukin-33 (IL-33) biological activity, optionally an IL-33 polypeptide or a biologically active fragment or homolog thereof; or any combination thereof.
A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
99.
METHODS, SYSTEMS, AND COMPUTER READABLE MEDIA FOR ANALYZING RESPIRATORY KINEMATICS
A method for analyzing respiratory kinematics includes collecting a plurality of kinematic signal data streams from each of a respective plurality of inertial sensor devices applied to a subject, wherein the kinematic signal data streams are synchronized with each other, transforming the plurality of kinematic signal data streams into a respective plurality of analytic signals, determining landmark points associated with each of the plurality of analytic signals to identify individual breathing intervals associated with each of the plurality of inertial sensor devices, and analyzing two or more of the individual breathing intervals to establish a magnitude-synchronicity relationship that is utilized to determine a probability of a presence of a respiratory condition existing in the subject.
A structure, method, and computer program product for a diabetes control system provides, but is not limited thereto, the following: open-loop or closed-loop control of diabetes that adapts to individual physiologic characteristics and to the behavioral profile of each person. An exemplary aspect to this adaptation is biosystem (patient or subject) observation and modular control. Consequently, established is the fundamental architecture and the principal components for a modular system, which may include algorithmic observers of patients' behavior and metabolic state, as well as interacting control modules responsible for basal rate, insulin boluses, and hypoglycemia prevention.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
